2 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMOCompleted
The objectives of this study are to assess and compare at 6 months 1) the percentage of subjects achieving bilateral uncorrected distance visual acuity and bilateral uncorrected near visual acuity <= 0.1 logMar; 2) spectacle independence at…